Thomas Dubensky
Direttore/Membro del Consiglio presso HTG MOLECULAR DIAGNOSTICS, INC.
Posizioni attive di Thomas Dubensky
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| HTG MOLECULAR DIAGNOSTICS, INC. | Direttore/Membro del Consiglio | 18/08/2022 | - |
ImmuneSensor Therapeutics, Inc.
 ImmuneSensor Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services ImmuneSensor Therapeutics, Inc. is a clinical-stage biotechnology company based in Dallas, TX. ImmuneSensor Therapeutics is building a pipeline of novel small molecule and adc immune stimulating candidates that aim to modulate the innate immune system. The company is led by a team of experienced biotech professionals who are committed to creating novel treatments that harness the body’s innate immune system to treat a wide range of diseases. ImmuneSensor Therapeutics is focused on discovering and developing novel therapies that leverage the incredible versatility and therapeutic potential of the cgas-sting pathway, which is one of the key pathways in the innate immunity system that works to detect both foreign and host-derived DNA. The company was founded in 2014 by Zhijian Chen and Jet Li, and the CEO is Ernest Wong. | Direttore/Membro del Consiglio | 01/05/2024 | - |
| Amministratore Delegato | 01/05/2024 | - | |
| Presidente | 01/05/2024 | - |
Storia della carriera di Thomas Dubensky
Precedenti posizioni note di Thomas Dubensky
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| TEMPEST THERAPEUTICS, INC. | Direttore/Membro del Consiglio | 01/09/2017 | 15/09/2023 |
| Presidente | 01/09/2017 | 15/09/2023 | |
| CHINOOK THERAPEUTICS, INC. | Direttore Tecnico/Scientifico/R&S | 01/09/2011 | 31/08/2017 |
| CERUS CORPORATION | Direttore Tecnico/Scientifico/R&S | 01/01/2002 | 16/11/2007 |
TempestTx, Inc.
 TempestTx, Inc. BiotechnologyHealth Technology TempestTx, Inc. is a clinical stage biotechnology company which engages in advancing small molecule therapeutics that modulate anti-tumor pathways. The company is headquartered in South San Francisco, CA. | Direttore/Membro del Consiglio | 01/01/2017 | - |
| Amministratore Delegato | 01/01/2017 | - | |
| Presidente | - | - | |
Chiron Viagene, Inc.
 Chiron Viagene, Inc. Miscellaneous Commercial ServicesCommercial Services Chiron Viagene, Inc. provides technical services and life science research. The company is based in San Diego, CA. The company specializes in EMSA reagents and services, as well as producing innovative technology. The company was founded by Paul K. Laikind, David F. Hale, Jack W. Reich, Harry E. Gruber. Chiron Viagene was acquired by Chiron Corp. on October 03, 1995 for $135 million. | Corporate Officer/Principal | - | - |
Chiron Corp.
 Chiron Corp. Medical SpecialtiesHealth Technology Chiron Corp. provides nucleic acid test for blood screening. Its products include tigris system, target capture system, reagent preparation incubator, and many more. The company was founded in 1981 by William J. Rutter, Edward E. Penhoet & Pablo Valenzuela and is headquartered in Emeryville, CA. | Direttore Tecnico/Scientifico/R&S | - | - |
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Corporate Officer/Principal | - | - |
| ░░░░░░ ░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | - |
| ░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | - |
| ░░░░░░░ | ░░░░░░░░░░ | - |
Formazione di Thomas Dubensky
| University of California, Berkeley | Undergraduate Degree |
| University of Colorado Health Sciences Center | Doctorate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 14 |
Posizioni
| Chief Tech/Sci/R&D Officer | 5 |
| Director/Board Member | 4 |
| President | 3 |
Settori
| Health Technology | 9 |
| Commercial Services | 4 |
| Consumer Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 3 |
|---|---|
| CERUS CORPORATION | Health Technology |
| HTG MOLECULAR DIAGNOSTICS, INC. | Commercial Services |
| TEMPEST THERAPEUTICS, INC. | Health Technology |
| Aziende private | 8 |
|---|---|
Chiron Corp.
Chiron Corp. Medical SpecialtiesHealth Technology Chiron Corp. provides nucleic acid test for blood screening. Its products include tigris system, target capture system, reagent preparation incubator, and many more. The company was founded in 1981 by William J. Rutter, Edward E. Penhoet & Pablo Valenzuela and is headquartered in Emeryville, CA. | Health Technology |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Health Technology |
Aduro BioTech, Inc.
 Aduro BioTech, Inc. Pharmaceuticals: MajorHealth Technology Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA. | Health Technology |
TempestTx, Inc.
TempestTx, Inc. BiotechnologyHealth Technology TempestTx, Inc. is a clinical stage biotechnology company which engages in advancing small molecule therapeutics that modulate anti-tumor pathways. The company is headquartered in South San Francisco, CA. | Health Technology |
Chiron Viagene, Inc.
Chiron Viagene, Inc. Miscellaneous Commercial ServicesCommercial Services Chiron Viagene, Inc. provides technical services and life science research. The company is based in San Diego, CA. The company specializes in EMSA reagents and services, as well as producing innovative technology. The company was founded by Paul K. Laikind, David F. Hale, Jack W. Reich, Harry E. Gruber. Chiron Viagene was acquired by Chiron Corp. on October 03, 1995 for $135 million. | Commercial Services |
Anza Therapeutics, Inc.
 Anza Therapeutics, Inc. Medical SpecialtiesHealth Technology Anza Therapeutics, Inc. develops products in the fields of cancer and infectious diseases. It also develops immunotherapy for infectious diseases, therapeutic vaccines for treating cancers that over-express Mesothelin and for treating people infected with the hepatitis C virus (HCV). The company was founded in 2007 and is headquartered in Concord, CA. | Health Technology |
Immune Design Corp.
 Immune Design Corp. Pharmaceuticals: MajorHealth Technology Immune Design Corp. is a clinical-stage immunotherapy company focused on cancer with in vivo approaches designed to enable the body's immune system to fight disease. It develops multiple product candidates from its discovery platforms, ZVex and GLAAS. The company was founded by Steven G. Reed and David Baltimore on February 20, 2008 and is headquartered in Kenilworth, NJ. | Health Technology |
ImmuneSensor Therapeutics, Inc.
ImmuneSensor Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services ImmuneSensor Therapeutics, Inc. is a clinical-stage biotechnology company based in Dallas, TX. ImmuneSensor Therapeutics is building a pipeline of novel small molecule and adc immune stimulating candidates that aim to modulate the innate immune system. The company is led by a team of experienced biotech professionals who are committed to creating novel treatments that harness the body’s innate immune system to treat a wide range of diseases. ImmuneSensor Therapeutics is focused on discovering and developing novel therapies that leverage the incredible versatility and therapeutic potential of the cgas-sting pathway, which is one of the key pathways in the innate immunity system that works to detect both foreign and host-derived DNA. The company was founded in 2014 by Zhijian Chen and Jet Li, and the CEO is Ernest Wong. | Commercial Services |
- Borsa valori
- Insiders
- Thomas Dubensky
- Esperienza
